Sales of Spectrum's drug Fusilev for patients with metastatic colorectal cancer remain strong heading into the remainder of 2014, said the company's CEO Rajesh Shrotriya. Total revenue was $46.9 million in Spectrum's second quarter, up 41% from the prior year. Fusilev accounted for $26.6 million of Spectrum's sales in the second quarter, or 56% of total revenue. Outside Fusilev, Shrotriya expects to make a Phase 3 Go/No-Go decision by the end of the year for SPI-2012, a long-acting GCSF drug which he believes could be a 'potential blockbuster'. Finally, Shrotriya said he is seeing a strong sales trajectory for Spectrum's drug Beleodaq for the treatment of patients suffering from peripheral T-cell lymphoma.